1Amsden GW,Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?[J].J Antimicrob Chemother,2005,55(1):10-21.
4Marston B J,Plouffe JF,File TM Jr,et al.Incidence of community acquired pneumonia requiring hospitalization,results of a population-based active surveillance study in Ohio,thecommunity-based pneumonia Incidence Study Group[J].Arch InternMed,1997,157:1709-1718.
5Julio A.Guidelines for community acquired pneumonia within disease management programs[J].Dis Manage Health Outcomes,2003,11:33-43.
6Thomas J.The Treatment of Commuity Acquired Pneumonia[J].Infect Dis Clin Pract,2004,12:S6-S9.
7Doern GV, Brueggemann AB, Huynh H, et al. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-1998[J]. Emerg Infect Dis,1999,5:757-765.
8Song JH, Lee NY, Ichiyama, et al. Spread of Drug-resistant Streptococcus pneumoniae in Asian countries: Asian network for surveillance of resistant pathogens (ANSORP) Study[J]. Clin Infect Dis,1999,28:1206-1211.
9Ip M, Lyon DJ, Yung RWH, et al. Evidence of clonal disemination of multidrug-resistant Streptococcus pneumoniae[J]. J Clin Microbiol,1999,37:2834-2839.
10Lefevre JC, Faucon G, Sicard AM, et al. DNA Fingerprinting of Streptococcus pneumoniae strains by pulsed-field gel electrophoresis[J]. J Clin Microbiol. 1993,31:2724-2728.
